Chemistry:DETQ
From HandWiki
DETQ is an experimental drug which acts as a positive allosteric modulator of the Dopamine receptor D1. It increases the D1-mediated response to endogenous dopamine levels, and was developed as a potential treatment for Parkinson's disease.[1][2][3][4][5]
See also
- Glovadalen
- Mevidalen
References
- ↑ "An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis". The Journal of Pharmacology and Experimental Therapeutics 360 (1): 117–128. January 2017. doi:10.1124/jpet.116.236372. PMID 27811173.
- ↑ "Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders". Neuropharmacology 128: 351–365. January 2018. doi:10.1016/j.neuropharm.2017.10.032. PMID 29102759.
- ↑ "Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders". Neuropsychotherapeutics. Advances in Pharmacology. 86. San Diego, Calif.: Elsevier. 2019. pp. 273–305. doi:10.1016/bs.apha.2019.06.001. ISBN 978-0-12-816668-0.
- ↑ "The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice". Behavioural Brain Research 361: 139–150. April 2019. doi:10.1016/j.bbr.2018.12.006. PMID 30521930.
- ↑ "The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux". Behavioural Brain Research 459. February 2024. doi:10.1016/j.bbr.2023.114766. PMID 38048913.
 |  |
